Further evidence in this presentation that the Dermatology Go to Market model is working and likely to be a big contributor to revenue and profit.
Epiduo (IQVIA $210 US) launched Feb 22- Market share 56%
Aczone (IQVIA $95 US) launched Feb 22. - Market share 31%
Absorica (IQVIA $140US) launched Sept 21 - Market share now 45% up from 39 in February update
Addionally,
Upsher-Smith , Mayne's Absorica partner, reported in May a 350% gain in revenue in dermatology due to Absorica.
Also 2 days ago Torrent, Mayne's Aczone partner made a small comment about an increase in US revenue aided by the launch of Dapsone (Aczone)
Further evidence in this presentation that the Dermatology Go to...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$4.95 |
Change
-0.200(3.88%) |
Mkt cap ! $402.1M | |||
| Open | High | Low | Value | Volume |
| $5.05 | $5.09 | $4.93 | $824.9K | 165.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 16429 | $4.95 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $5.08 | 5000 | 1 |
View Market Depth
| Last trade - 16.10pm 31/07/2025 (20 minute delay) ? |
| MYX (ASX) Chart |